Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - potassium chloride, quantity: 2.98 g/l; sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.

United States - English - NLM (National Library of Medicine)

hospira, inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium acetate anhydrous (unii: nvg71zz7p0) (sodium cation - unii:lyr4m0nh37), sodium gluconate (unii: r6q3791s76) (sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838) - sodium chloride 526 mg in 100 ml - normosol-r ph 7.4 is indicated for replacement of acute extracellular fluid volume losses in surgery, trauma, burns or shock. normosol-r ph 7.4 also can be used as an adjunct to restore a decrease in circulatory volume in patients with moderate blood loss. normosol-r ph 7.4 is not intended to supplant transfusion of whole blood or packed red cells in the presence of uncontrolled hemorrhage or severe reductions of red cell volume. normosol-r ph 7.4 is particularly valuable as a solution for use in starting blood, i.e., as a priming solution for the infusion set. no hemolysis of blood is seen at the interface or with mixed solution and blood. it may also be used as a diluent to aid in the transfusion of packed red blood cells (prbc). normosol-r ph 7.4 and physiologic saline solution (0.9% sodium chloride injection, usp) are compatible with both young and old prbc. none known.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - ropivacaine hydrochloride monohydrate, quantity: 52.9 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections; sodium hydroxide - surgical anaesthesia (adults and children over 12 years of age),? epidural block for surgery including caesarean section,? intrathecal anaesthesia,? field block (minor nerve block and infiltration),? major nerve block,analgesia (adults and children over 12 years of age),? continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain,? field block (minor nerve block and infiltration),? continuous peripheral nerve block infusion or intermittent injections for post operative pain management,? continuous wound infusion for postoperative pain management (adults only),analgesia (children aged 0 - 12 years),? caudal epidural block in neonates (> 37 weeks gestation and over 2500 g weight), infants and children up to and including 12 years,? continuous epidural infusion in infants (> 30 days and over 2500 g weight) and children up to and including 12 years,? peripheral nerve block in children aged 1 up to and including 12 years,for peri- and postoperative pain management.,there are no safety or efficacy data to support the use of ropivacaine actavis for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections and for continuous wound infusion support the use for up to 48 hours only).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - ropivacaine hydrochloride monohydrate, quantity: 105.8 mg - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - surgical anaesthesia (adults and children over 12 years of age),? epidural block for surgery including caesarean section,? intrathecal anaesthesia,? field block (minor nerve block and infiltration),? major nerve block,analgesia (adults and children over 12 years of age),? continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain,? field block (minor nerve block and infiltration),? continuous peripheral nerve block infusion or intermittent injections for post operative pain management,? continuous wound infusion for postoperative pain management (adults only),analgesia (children aged 0 - 12 years),? caudal epidural block in neonates (> 37 weeks gestation and over 2500 g weight), infants and children up to and including 12 years,? continuous epidural infusion in infants (> 30 days and over 2500 g weight) and children up to and including 12 years,? peripheral nerve block in children aged 1 up to and including 12 years,for peri- and postoperative pain management.,there are no safety or efficacy data to support the use of ropivacaine actavis for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections and for continuous wound infusion support the use for up to 48 hours only).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 20mmol/10ml) solution for infusion 10ml ampoules (hameln pharma ltd - potassium chloride - solution for infusion - 150mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 20mmol/10ml) solution for infusion 10ml ampoules (advanz pharma - potassium chloride - solution for infusion - 150mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - sodium chloride, quantity: 6 g/l; sodium lactate, quantity: 6.24 g/l; potassium chloride, quantity: 0.4 g/l; calcium chloride dihydrate, quantity: 0.27 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. may also be used as a solvent for intravenously administered drugs where compatibility has been established. indications as at 22 august 2005 : compound sodium lactate solution is particularly suitable for replacement of extracellular fluid loss where isotonic dehydration is evident and in burn therapy.

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - sodium chloride - solution for infusion - 0.9 percent weight/volume - sodium chloride

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - sodium chloride - solution for infusion - 0.9 percent weight/volume - sodium chloride

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - sodium chloride - solution for infusion - 0.9 percent weight/volume - sodium chloride